TMX Newsfile·2026-01-28 18:14Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Alvotech due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Alvotech's stock price experienced a significant decline of 34% on November 3, 2025, following the announcement of a complete response letter (CRL) from the U.S. FDA regarding its Biologics License Application (BLA) for AVT05 [3]. - The CRL indicated that certain deficiencies identified during the FDA's pre-license inspection of Alvotech's Reykjavik manufacturing facility must be resolved before the BLA for AVT05 can be approved [3]. Group 2: Legal Actions - Investors who purchased Alvotech securities may be eligible for compensation through a class action lawsuit being prepared by Rosen Law Firm, which operates on a contingency fee basis [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering substantial amounts for investors [4].